Eikon Therapeutics, Inc. — fact timeline

Ma. Fatima D. Francisco was appointed as Class I director at Eikon Therapeutics, Inc..

“the Board of Directors (the “Board”) of Eikon Therapeutics, Inc. (the “Company”) appointed Ma. Fatima D. Francisco to the Board as a Class I director, effective June 15, 2026.”

Eikon Therapeutics, Inc. reported first quarter 2026 results: net income $83.0 million.

“Net loss attributable to common stockholders was $83.0 million for the first quarter of 2026, as compared to $74.5 million for the prior-year period.”

Eikon Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2025 results: net income Net loss attributable to common stockholders was $79.7 million for the fourth quarter of 2025.

“On March 30, 2026, Eikon Therapeutics, Inc. issued a press release announcing clinical and corporate updates and its financial results for the three months and full year ended December 31, 2025”

Eikon Therapeutics, Inc.: Adopted amended and restated bylaws effective as of February 6, 2026, in connection with the closing of the IPO (effective 2026-02-06).

“Effective as of February 6, 2026, the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.”

Eikon Therapeutics, Inc.: Filed an amended and restated certificate of incorporation effective immediately prior to closing of IPO (effective 2026-02-06).

“In connection with the closing of the initial public offering (the “IPO”) of shares of common stock of Eikon Therapeutics, Inc. (the “Company”) on February 6, 2026, the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware.”